| Trial ID: | L5020 |
| Source ID: | NCT04627402
|
| Associated Drug: |
Conbercept And Ta
|
| Title: |
Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)
|
| Acronym: |
CONTE
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Macular Edema
|
| Interventions: |
DRUG: Conbercept and TA|DRUG: Conbercept
|
| Outcome Measures: |
Primary: Macular thickness, Change in mean central subfield thickness from randomization visit measured with optical coherence tomography., 24 weeks | Secondary: Best-corrected visual acuity (BCVA), Change in BCVA letter score from randomization visit as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS)., 48 weeks|Treatment number, The number of intravitreous injection treatments, 48 weeks|Incidence of complications, The incidence of cataract and glaucoma, 48 weeks
|
| Sponsor/Collaborators: |
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2020-11-12
|
| Completion Date: |
2021-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2020-11-17
|
| Locations: |
Zhongshan Opthalmic Center, Guangzhou, Guangdong, 510060, China
|
| URL: |
https://clinicaltrials.gov/show/NCT04627402
|
